Skip to content

Comparison of the Effects of Fentanyl, Oxycodone, Butorphanol on Gastrointestinal Function

Comparison of the Effects of Fentanyl, Oxycodone, Butorphanol on Gastrointestinal Function in Patients Undergoing Laparoscopic Hysterectomy: a Double-blind, a Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04295109
Enrollment
105
Registered
2020-03-04
Start date
2020-03-02
Completion date
2020-07-31
Last updated
2020-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenomyosis, Cervix Neoplasms, Endometrial Cancer, Fibroid Uterus

Brief summary

Postoperative ileus (POI) is a transient loss of coordinated peristalsis precipitated by surgery and exacerbated by opioid pain medication.So,how to provide patients with ideal analgesia without affecting the recovery of postoperative gastrointestinal function?This was a prospective randomized controlled study. A total of 105 patients who were scheduled for laparoscopic hysterectomy were randomly selected from The First Affiliated Hospital with Nanjing Medical University by random number table. These patients were randomly divided into three groups: fentanyl(F) group, oxycodone(O) group and butorphanol(B) group.

Detailed description

Background: Patients often experience pain after gynecological laparoscopy. However, the use of opioid analgesia after surgery may increase the incidence of postoperative ileus (POI). Postoperative ileus (POI) is a common surgical emergency after a surgical procedure, leading to infection and intestinal adhesions, which can extend hospitalization and increase readmission rates, and consequently increasing healthcare costs. How to provide patients with ideal analgesia without affecting the recovery of postoperative gastrointestinal function? There is no guideline which has been troubling clinical anesthesiologists. Aims: To observe the effects of fentanyl, oxycodone, Butorphanol on the recovery of gastrointestinal function after laparoscopic hysterectomy. Methods: A total of 105 patients undergoing laparoscopic hysterectomy were randomly divided to three groups: fentanyl group(group F), butorphanol group(group B), or oxycodone group(group O). The primary outcome measures were postoperative time to first anal exhaust the total analgesic doses in PCIA,effective bolus times. Patients were also assessed for pain with a visual analogue scale (VAS), the cumulative PCIA dose, adverse effects (Nausea,vomiting, bradycardia, respiratory depression and pruritus), sedation level at 4, 12, 24, and 48 hours postoperatively, and satisfaction during the postoperative 48 hours and postoperative hospitalization days.

Interventions

DRUGthe drug of intravenous patient-controlled analgesia

At present, opioids are most widely used in postoperative analgesia. This study aims to use different opioid receptor agonists---fentanyl, oxycodone and butorphanol for analgesia after laparoscopic hysterectomy.Compare the recovery of gastrointestinal function after operation.

Sponsors

The First Affiliated Hospital with Nanjing Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
40 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

1. patients who were scheduled for laparoscopic hysterectomy from W&C BRANCH HOSPITAL OF JIANGSU PROVINCE HOSPITAL 2. American Society of Anesthesiologists (ASA) physical status classification 1 to 2, 3. Women aged 40-65 4. Weight 50-80 kg

Exclusion criteria

1. History of opioids abuse and allergy and contraindication to opioid drugs 2. bronchial asthma; coronary heart disease; severe hypertension; diabetes mellitus; 3. hepatic, and renal dysfunction (glutamyl aminotransferase\> 40U or aspartate aminotransferase\> 35U; urea nitrogen\> 8.2 μmol / L, creatinine\> 133 μmol / L), 4. History of brain damage or psychiatric disease 5. Patients with coagulopathy (PT\> 17 seconds or activated partial thromboplastin time (APTT)\> 47 seconds); 6. pregnant or lactating women; 7. Those with long-term constipation; 8. History of digestive diseases; 9. history of gastrointestinal disease (peptic ulcer disease, Crohn's disease, or ulcerative colitis) 10. Participants in other drug trials in the past three months. (11)After randomization and allocation, patients were withdrawn if laparoscopy was converted to open surgery or if they required reinvestigation for postoperative bleeding.

Design outcomes

Primary

MeasureTime frameDescription
postoperative time to first anal exhaustFrom date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 15 daysTiming from the end of the operation
the cumulative dose administered in the patient-controlled modeFrom date of operation until the date of first documented progression of anal exhaust , assessed up to 48 hoursThe cumulative dose administered in the patient-controlled mode during the initial 48 hours after the operation was measured
effective bolus timesFrom date of operation until the date of first documented progression of anal exhaust , assessed up to 48 hoursThe effective bolus times in the patient-controlled mode during the initial 48 hours after the operation was measured

Secondary

MeasureTime frameDescription
patients' degree of overall satisfaction with the postoperative analgesiaat 48 hours postoperativelyPatients were asked to evaluate their degree of overall satisfaction with the postoperative analgesia on a 11-point scale (0= very unsatisfied, 1-3= unsatisfied, 4-6 = neutral, 7-9= satisfied, or 10 = very satisfied).
pain scoreat 4 hours postoperativelyby using numerical rating scale (NRS):The pain scale ranged from 0 (=no pain) to 10 (=worst pain imaginable)
postoperative hospitalization daysFrom date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 15 daysAll patients were cured in accordance with clinical cure standard
Sedation scoreat 4 hours postoperativelyby using Ramsay scale(1=anxious and agitated or restless, or both; 2=cooperative, oriented, and tranquil; 3=responds to command only; 4=asleep, but has a brisk response to light tactile stimulus or a simple verbal command; 5=asleep, but arousable only by strong physical stimulus; and 6=asleep, unarousable)
adverse effectsat 4 hours postoperativelyNausea 、vomiting 、bradycardia(HR \<60 beats min-1)、respiratory depression(According to practice guidelines from the ASA, clinical signs of opioid-induced respiratory depression are respiratory rate \<10 bpm, arterial O2 saturation \<90%, or arterial CO2 tension \>6.66 kPa) and pruritus

Countries

China

Contacts

Primary ContactCunming Liu, doctorate
1335587409@qq.com13951890866
Backup ContactMinna Guo, Master
1653474602@qq.com18835162576

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026